Sherry K M, Locke T J
Northern General Hospital, Sheffield, UK.
Cardiovasc Drugs Ther. 1993 Aug;7(4):671-5. doi: 10.1007/BF00877820.
Milrinone is shown in 10 patients to be a valuable pharmacological bridge to heart transplantation; it can stabilize and improve decompensated chronic heart failure (CHF) in cases where the response to beta-agonists is inadequate. One patient who had suffered an acute myocardial infarction with heart failure resistant to vasodilators, beta-agonists, and balloon counterpulsation was stabilized with milrinone for 21 days. He was then maintained on ACE inhibitors until heart transplantation 3 months later. The other nine patients with severe decompensated CHF were stabilized on milrinone for between 11 and 51 days. Seven of them received a donor heart. Two patients died of bacteremic shock and terminal heart failure before a suitable organ could be found (31 and 51 days). All patients were clinically improved within 48 hours of the addition of IV milrinone to their therapy. In 55 patients following cardiac surgery, the efficacy and safety of milrinone in the treatment of low cardiac output states is demonstrated. Milrinone has a useful role in the management of patients with circulatory failure both before and after cardiac surgery, and this paper reviews the relevant current literature.
米力农在10例患者中显示出是心脏移植的一种有价值的药物桥梁；在对β受体激动剂反应不足的情况下，它可以稳定并改善失代偿性慢性心力衰竭（CHF）。一名患有急性心肌梗死且心力衰竭对血管扩张剂、β受体激动剂和球囊反搏均无反应的患者，使用米力农稳定病情达21天。然后他一直服用血管紧张素转换酶抑制剂，直到3个月后进行心脏移植。其他9例严重失代偿性CHF患者使用米力农稳定病情11至51天。其中7例接受了供体心脏。2例患者在找到合适器官之前死于菌血症休克和终末期心力衰竭（分别为31天和51天）。所有患者在静脉注射米力农加入治疗后的48小时内临床症状均有改善。在55例心脏手术后的患者中，证明了米力农治疗低心排血量状态的有效性和安全性。米力农在心脏手术前后循环衰竭患者的管理中具有重要作用，本文综述了相关的当前文献。
